FDA panel backs Bepreve, rebuffs Rejena

FDA's Dermatologic and Ophthalmic Drugs Advisory Committee voted 7-0 on Friday to recommend approval of Bepreve bepotastine from Ista Pharmaceuticals Inc. (NASDAQ:ISTA) to treat ocular itching associated with allergic conjunctivitis. The PDUFA date is Sept. 12. Bepreve is an eye drop formulation of a selective histamine H1 receptor antagonist. Ista gained $0.45 (11%) to $4.69. ...